

Tuesday 19.5.2015

16:30-17:30

Opening lecture

Chair: Roland Jonsson

A tissue-based map of the human proteome

Fredrik Ponten, Sweden

Wednesday 20.5.2015

Session 1. Classification criteria

9:00-9:40

S1.1

Proposed ACR-EULAR Classification Criteria for Sjögren's Syndrome: Development and Validation

Caroline Shiboski, Stephen Shiboski, USA

9:40-9:50

S1.3

Fulfillment of classification criteria of cryoglobulinemic vasculitis (CryoVas) is associated with a higher systemic activity in patients with primary Sjögren syndrome

Pilar Brito-Zerón, Spain.

9:50-10:00

S1.10

Development of ClinESSDAI score (Clinical EULAR Sjögren's Syndrome Disease Activity Index) without biological domain: a tool for biological studies

Raphaelle Seror, France

Coffee break

Session 2. New diagnostic tools

10:20-10:40

S2.1

Is salivary gland ultrasonography a useful tool in Sjögren's syndrome? A systematic review.

Valerie Devauchelle-Pensec, France

10:40-10:50

S2.10

Characterization of early and progressive autoimmunity in Sjögren's Syndrome: the incomplete Sjögren's Syndrome model.

Astrid Rasmussen, USA

10:50-11:00

S2.7

Sonoelastography evaluation of salivary glands in primary Sjögren's syndrome

Xia Zhang, China

11:00-11:10

S2.5

Salivary gland ultrasonography: towards a simplified scoring system for the clinical and functional assessment of patients with primary and secondary Sjögren's syndrome

Chiara Baldini, Italy

11:10-11:25

Instruction video: Performing a parotid gland biopsy

Fred Spijkervet, The Netherlands

Coffee break

Session 3. New biomarkers for Sjögren's syndrome

11:40-12:00

S3.1

Biomarkers in Sjögren's syndrome

Athanasios G Tzioufas, Greece

12:00-12:10

S3.6

Metabolomics in primary Sjögren's syndrome: data from the ASSESS cohort

Jacques-Eric Gottenberg, France

12:10-12:20

S3.14

Metagenomic Analysis of Salivary Exosome Transcriptomes from Patients with Primary Sjögren's Syndrome Using RNA-Seq

Ana Cotrim, USA

12:20-12:30

S3.3

Sjögren's syndrome patients with ectopic germinal centers present with a distinct salivary proteome

Nicolas Delaleu, Norway

12:30-13:30

Lunch

13:30-14:30

Poster session 1 (S1-S7)

Session 4. Classical sicca symptoms – oral and eye

14:30-14:50

S4.1

Oral manifestations of Sjögren's syndrome

Arjan Vissink, The Netherlands

14:50-15:10

S4.2

Keratoconjunctivitis Sicca in Sjögren's Syndrome

Stephen C. Pflugfelder, USA

15:10-15:20

S4.11

IP₃R deficit in acinar cells underlies loss of salivary gland fluid secretion in the autoimmune exocrinopathy, Sjögren's Syndrome

Leyla Teos, USA

15:20-15:30

S4.12

TNF- α and IL-20 affect the glandular secretion by modulating the calcium-signalling in human salivary acinar cells

Ellen Kaas, Denmark.

Coffee break

Session 5. Extraglandular manifestations

15:45-16:05

S5.1

Fatigue

Roald Omdal, Norway

16:05-16:25

S5.2

Interstitial lung diseases, current definitions and diagnostic challenges

Tomas M. Eagan, Norway

16:25-16:35

S5.5

A transcriptional signature of fatigue derived from patients with primary Sjögren's Syndrome

Katherine James, UK

16:35-16:45

S5.10

Cognitive symptoms are common in primary Sjögren's syndrome and are associated with anxiety

Katie Hackett, UK

Coffee break

Session 6. Patient panel

17:00-17:20

S6.1

Sjögren's Syndrome Foundation (SSF) Clinical Practice Guidelines for Systemic Management: Treatment of Inflammatory Musculoskeletal (MSK) Pain, Fatigue and Use of Biologics

Steven Carsons, USA

17:20-17:40

S6.2

International Sjogren's Network of Patient Organizations

Steven Taylor, USA

17:40-18:00 Discussions

Speakers dinner (by invitation only)

Thursday 21.5.2015

Session 7. Immune cells in Sjögren's syndrome

9:00-9:20

S7.1

B cells in Sjögren's syndrome: To be or not to be depleted

Jacques-Olivier Pers, France

9:20-9:30

S7.17

IL-33 secreted by M2 macrophage promotes the pathogenesis of IgG4-related disease

Sachiko Furukawa, Japan

9:30-9:40

S7.3

Analysis of naive, memory and granzyme B expressing peripheral B cell subset in Sjögren's syndrome

Gábor Papp, Hungary

9:40-9:50

S7.13

Circulating Precursor CCR7^{lo}PD-1^{hi}CXCR5⁺CD4⁺ T Cells Indicate Disease Activity in Sjögren's syndrome

Jing He, China

Coffee break

Session 8. Type I interferons in Sjögren's syndrome

10:15-10:35

S8.1

Interferon activation in Primary Sjögren's syndrome: a biomarker and pathogenic factor?

Marjan A. Versnel, The Netherlands

10:35-10:55

S8.2

Interferon Signature in Primary Sjögren's Syndrome

Jacques-Eric Gottenberg, France

10:55-11:05

S8.8

Fatigue or Tolerance-induction in Primary Sjögren's syndrome: A detrimental or beneficial role forIDO and the Tryptophan-Kynurenine pathway?

Naomi I Maria, The Netherlands

11:05-11:15

S8.4

Type I and II interferon signatures in Sjogren's syndrome: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis

Clio P. Mavragani, Greece

Coffee break

Session 9. Autoantibodies and autoantigens

11:30-11:50

S9.1

High-resolution mass spectrometric sequencing of secreted immunoglobulin proteomes in primary Sjögren's syndrome reveals clonotypic anti-Ro/La autoantibody sharing and heavy-chain repertoire expansion

Tom P. Gordon, Australia

11:50-12:10

S9.2

Recombinant monoclonal antibodies derived from salivary gland infiltrating antibody secreting cells

R Hal Scofield, USA

12:10-12:20

S9.16

Single-Cell Production and Characterization of Fully-Human Monoclonal Antibodies from the Minor Salivary Glands of Sjögren's Patients

Kristi A. Koelsch, USA

12:20-12:30

S9.17

Next-generation sequencing demonstrates dynamic recirculation of B cell clones in ectopic lymphoid structures of Sjögren's syndrome.

William Murray-Brown, UK

12:30-13:30

Lunch

13:30-14:30

Poster session 2 (S8-S15)

Session 10. Lymphoma in Sjögren's syndrome

14:30-14:50

S10.1

Transition to lymphoma in Sjögren's syndrome

Xavier Mariette, France

14:50-15:00

S10.2

Germline variant of TNFAIP3/A20 promotes B cell malignant transformation in primary Sjögren's syndrome patients. Meta-analysis of Data from France and UK

Gaetane Nocturne, France

15:00-15:10

S10.7

Sporadic occurrence of non-diagnosed IgG4-related disease in lymphoma patients with a previous Sjögren's syndrome diagnosis

Lilian Vasaitis, Sweden

15:10-15:20

S10.10

Activation of NFkB Pathways in Sjögren's Syndrome Related Lymphomagenesis-Role of the His159Tyr Mutation of the BAFF-R Receptor

Clio P. Mavragani, Greece

Coffee break

Session 11. Genetic aspects of Sjögren's syndrome

15:45-16:05

S11.1

Insights into Sjögren's Syndrome Etiology Through Discovery of Genetic Risk Variants

Kathy L. Sivils, USA

16:05-16:25

S11.2

Epigenetic Signatures of Salivary Gland Inflammation in Sjögren's Syndrome

Lindsey A. Criswell, USA

16:25-16:35

S11.3

Genome-wide analysis of DNA methylation profiles in multiple tissues in primary Sjögren's Syndrome

Juliana Imgenberg-Kreuz, Sweden

16:35-16:45

S11.6

Defective regulation of L1 endogenous retroelements in primary Sjogren's syndrome and systemic lupus erythematosus: Role of methylating enzymes

Clio P. Mavragani, Greece

Coffee break

Session 12. Animal models for Sjögren's syndrome

17:00-17:20

S12.1

Th17 cells: the culprit for sexual dimorphism in Sjögren's syndrome

Cuong Q. Nguyen, USA

17:20-17:30

S12.5

ICOS-ICOSL modulates tertiary lymphoid organs formation, regulating the lymphotoxin pathway in an animal model of Sjögren's syndrome

Joana Dias De Campos, UK

17:30-17:40

S12.6

Aquaporin gene therapy corrects exocrine gland dysfunction and inflammation in mouse model of Sjögren's syndrome.

Jay A. Chiorini, USA

17:40-17:50

S12.10

IL22 regulates autoantibody production by inducing lymphoid chemokine expression in tertiary lymphoid organs

Saba Nayar, UK

19:00 Conference Dinner at Fløyen

Friday 22.5.2015

Session 13. Treatment

9:00-9:20

S13.1

Treatment of Extraglandular Manifestations of Sjögren's syndrome: The View from San Diego

Robert I. Fox, USA

9:20-9:40

S13.2

New systemic treatment options in primary Sjögren's syndrome

Hendrika Bootsma, The Netherlands

9:40-9:50

S13.3

Investigation of repeat BCG vaccinations in autoimmunity: Rationale and phase I trial in Sjögren's syndrome

Denise L. Faustman, USA

9:50-10:00

S13.4

Biologics, the next generation of approved topical anti-inflammatory interventions for dry eye disease: LFA-ICAM binding inhibition, IL-1 receptor antagonism and recombinant human serum albumin

John D Sheppard, USA

Coffee break

Session 14. Personalized and cell-based treatment

10:15-10:35

S14.1

Monitoring of therapeutic effects of biological therapeutics and small molecule inhibitors by single cell signaling profiling of blood cells

Bjørn Tore Gjertsen, Norway

10:35-10:55

S14.2

A dendritic cell-based therapy for rheumatoid arthritis

Catharien Hilkens, UK

10:55-11:05

S14.3

Development of the Sjögren's Syndrome Responder Index (SSRI), a Data-Driven Composite Endpoint for Assessing Treatment Efficacy

Divi Cornec, France

11:05-11:15

S14.6

Baseline characteristics of parotid gland histopathology predict responsiveness of patients with primary Sjögren's syndrome to rituximab treatment.

Konstantina Delli, The Netherlands.

Coffee break

Session 15. Biobanks, registries and international networking

11:30-11:50

S15.1

Integrated international collaborations in Sjögren's Syndrome: the eSSential (EULAR Sjögren's Syndrome Experimental aNd Translational Investigative Alliance) study group.

Francesca Barone, UK

11:50-12:10

S15.2

Clinical and immunological characterization at diagnosis of 5041 patients with primary Sjögren syndrome fulfilling the 2002 AE classification criteria: The Big Data International Sjögren Project

Manuel Ramos-Casals, Spain

12:10-12:20

S15.6

Characterization of baseline systemic activity using the new ClinESSDAI in the Big Data Sjögren Project Cohort: Analysis in 3316 patients

Pilar Brito-Zerón, Spain

12:20-12:30

S15.4

Smokers have reduced risk of primary Sjögren's syndrome (pSS), and smoke cessation may trigger development of the disease

Peter Olsson, Sweden

Closing remarks – Roland Jonsson

12:45-13:30

Lunch